What is the 13F Pro Quality Score for ALXO?

13F Pro ranks ALX ONCOLOGY HOLDINGS INC (ALXO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ALXO's current score at https://13fpro.ai/research/ALXO (free sign-up required for the full ranking).

Where does 13F Pro source ALXO data?

All ALX ONCOLOGY HOLDINGS INC fundamentals and ownership data come directly from SEC EDGAR. ALX ONCOLOGY HOLDINGS INC files with the SEC under CIK 1810182. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ALXO in?

ALX ONCOLOGY HOLDINGS INC (ALXO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ALXO research updated on 13F Pro?

ALXO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ALX ONCOLOGY HOLDINGS INC(ALXO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1810182 ALXO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ALXO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ALX ONCOLOGY HOLDINGS INC (ALXO), a Healthcare sector company. ALXO is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), ALX ONCOLOGY HOLDINGS INC reports net income of $-17.9M, free cash flow of $-18.7M. Top institutional holders of ALXO by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., TCG Crossover Management,, venBio Partners, based on the most recent SEC filings. ALXO trades on the Nasdaq exchange and files with the SEC under CIK 1810182. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALXO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ALX ONCOLOGY HOLDINGS INC directly from SEC EDGAR.

Net Income

Q1 2026

$-17.9M

Free Cash Flow

Q1 2026

$-18.7M

D/E Ratio

Q1 2026

0.09

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 $0.00FY23 —FY24 —FY25 —

Net Income

+24.6% YoY

$-101.7MFY 2025

FY22 $-123.5MFY23 $-160.8MFY24 $-134.8MFY25 $-101.7M

Operating Income

+27.0% YoY

$-104.0MFY 2025

FY22 $-127.4MFY23 $-170.3MFY24 $-142.5MFY25 $-104.0M

EPS (Diluted)

+26.4% YoY

$-1.90FY 2025

FY22 $-3.03FY23 $-3.74FY24 $-2.58FY25 $-1.90

Total Assets

-60.0% YoY

$59.0MFY 2025

FY22 $306.5MFY23 $242.6MFY24 $147.8MFY25 $59.0M

Total Debt

+39.4% YoY

$15.4MFY 2025

FY22 $10.6MFY23 $10.6MFY24 $11.0MFY25 $15.4M

Op. Cash Flow

+31.0% YoY

$-84.1MFY 2025

FY22 $-89.2MFY23 $-130.4MFY24 $-121.9MFY25 $-84.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	—	—	—	$0.00	$0.00 -100.0%	$1.2M
Net Income	$-101.7M +24.6%	$-134.8M +16.1%	$-160.8M -30.2%	$-123.5M -47.9%	$-83.5M -82.5%	$-45.7M
Operating Income	$-104.0M +27.0%	$-142.5M +16.3%	$-170.3M -33.6%	$-127.4M -52.5%	$-83.6M -91.4%	$-43.7M
EPS (Diluted)	$-1.90 +26.4%	$-2.58 +31.0%	$-3.74 -23.4%	$-3.03 -46.4%	$-2.07 +25.0%	$-2.76
Total Assets	$59.0M -60.0%	$147.8M -39.1%	$242.6M -20.9%	$306.5M -19.4%	$380.2M -12.8%	$436.1M
Total Debt	$15.4M +39.4%	$11.0M +4.1%	$10.6M +0.0%	$10.6M	—	—
Operating Cash Flow	$-84.1M +31.0%	$-121.9M +6.5%	$-130.4M -46.1%	$-89.2M -31.0%	$-68.1M -77.9%	$-38.3M

AI Insight: ALXO Financial Trends

ALX Oncology's quarterly losses improved from $39M to $18M over eight quarters, but equity swung dramatically from $26M to $151M in Q1 2026.

• Net losses steadily declined from $39M in Q2 2024 to $18M in Q1 2026, showing improving cost management.

• Operating cash flow losses narrowed from $27M in Q2 2024 to $19M in Q1 2026 despite quarterly volatility.

• Equity collapsed from $159M in Q2 2024 to $26M in Q4 2025 before jumping to $151M in Q1 2026.

⚠ Equity's dramatic $125M increase in Q1 2026 suggests potential equity raise that requires monitoring for dilution impact.

⚠ Company remains pre-revenue with consistent cash burn despite improvement trends, requiring funding runway assessment.

AI Insight: ALXO Ratio Trends

ALX Oncology's return ratios improved dramatically in Q1 2026, with ROE recovering to -47.4% from -197.7% in Q3 2025.

• ROE improved sharply from -197.7% in Q3 2025 to -47.4% in Q1 2026, the best level since Q2 2024.

• ROIC recovered to -45.9% in Q1 2026 from deeply negative levels throughout 2025.

• Debt-to-equity ratio declined to 0.09 in Q1 2026 from peak of 0.59 in Q4 2025.

⚠ All return metrics remain deeply negative despite improvement, indicating ongoing operational losses.

⚠ Debt-to-equity ratio spiked from 0.14 to 0.59 through 2025 before recent decline.

Get alerted when ALXO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ALX ONCOLOGY HOLDINGS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ALXO

RA CAPITAL MANAGEMENT, L.P.
$26.1M13,011,849 sh
TCG Crossover Management, LLC
$26.1M13,011,849 sh
venBio Partners LLC
$25.8M12,884,638 sh
Redmile Group, LLC
$16.0M7,964,188 sh
Blackstone Inc.
$11.7M5,826,544 sh
DRIEHAUS CAPITAL MANAGEMENT LLC
$11.5M5,734,620 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.4M4,179,736 sh
MARSHALL WACE, LLP
$7.5M3,757,216 sh
Vivo Capital, LLC
$6.4M3,184,713 sh
Almitas Capital LLC
$6.4M3,173,834 sh

Fund	Value	Shares
RA CAPITAL MANAGEMENT, L.P.	$26.1M	13,011,849
TCG Crossover Management, LLC	$26.1M	13,011,849
venBio Partners LLC	$25.8M	12,884,638
Redmile Group, LLC	$16.0M	7,964,188
Blackstone Inc.	$11.7M	5,826,544
DRIEHAUS CAPITAL MANAGEMENT LLC	$11.5M	5,734,620
VANGUARD CAPITAL MANAGEMENT LLC	$8.4M	4,179,736
MARSHALL WACE, LLP	$7.5M	3,757,216
Vivo Capital, LLC	$6.4M	3,184,713
Almitas Capital LLC	$6.4M	3,173,834

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ALXO on your watchlist

Track score changes the day ALX ONCOLOGY HOLDINGS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ALXO a good stock to buy?

13F Pro's AI-powered analysis of ALX ONCOLOGY HOLDINGS INC (ALXO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALXO are available on the ALXO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ALXO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALXO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ALX ONCOLOGY HOLDINGS INC's investment landscape.